Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients (Q41564156)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 January 2015

Language	Label	Description	Also known as
English	Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients	scientific article published on 3 January 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Philippe Flandre

21

object named as

Philippe Flandre

0 references

Anne-Geneviève Marcelin

22

object named as

Anne-Genevieve Marcelin

0 references

Hélène Le Guillou-Guillemette

16

object named as

Hélène Le Guillou-Guillemette

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

ANRS AC11 Resistance Study Group

23

object named as

ANRS AC11 Resistance Study Group

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

19

object named as

Diane Descamps

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Charlotte Charpentier

2

object named as

Charlotte Charpentier

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Stéphanie Raymond

0 references

Constance Delaugerre

7

object named as

Constance Delaugerre

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

1

object named as

Slim Fourati

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Mary-Anne Trabaud

6

object named as

Mary-Anne Trabaud

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Dominique Bettinger

15

object named as

Dominique Bettinger

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

14

object named as

Francis Barin

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Anne Signori-Schmuck

18

object named as

Anne Signori-Schmuck

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

17

object named as

Sophie Vallet

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Anne M Maillard

10

object named as

Anne Maillard

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

3

object named as

Corinne Amiel

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Sandrine Reigadas

5

object named as

Sandrine Reigadas

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

8

object named as

Florence Nicot

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Audrey Rodallec

9

object named as

Audrey Rodallec

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

11

object named as

Audrey Mirand

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Hélène Jeulin

12

object named as

Hélène Jeulin

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

author name string

Laurence Morand-Joubert

4

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Brigitte Montès

13

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Vincent Calvez

20

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

language of work or name

0 references

publication date

3 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

1507-1512

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Raltegravir and etravirine are active against HIV type 1 group O.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Risk factors for raltegravir resistance development in clinical practice

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU535

21 January 2018

Identifiers

10.1093/JAC/DKU535

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41564156&oldid=1924373420"